N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: Preparation, characterization and its study on in situ intestinal perfusion

Drug Development and Industrial Pharmacy

Volumn 40, Issue 6, 2014, Pages 774-782

  Yu, Fan ^a,b   He, Chenghua ^a   Waddad, Ayman Y ^a   Munyendo, Were L L ^a   Lv, Huixia ^a   Zhou, Jianping ^a   Zhang, Qiang ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b YANCHENG TEACHERS UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Absorption enhancer; Arginine; Gambogic acid; Micelle; N octyl N arginine chitosan

Indexed keywords

ARGININE; CHITOSAN; GAMBOGIC ACID; N OCTYL N ARGININE CHITOSAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; MICELLE; N-OCTYL-N-ARGININE CHITOSAN; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC FORCE MICROSCOPY; COLON; CONTROLLED STUDY; DIALYSIS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DUODENUM; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; IN VITRO STUDY; INTESTINE PERFUSION; JEJUNUM; LIGHT SCATTERING; MALE; MICELLE; NONHUMAN; PARTICLE SIZE; PERITONEAL CAVITY; RAT; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHINESE MEDICINE; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG FORMULATION; DRUG STABILITY; INTESTINE; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; PERFUSION; PERMEABILITY; SOLUBILITY; SPRAGUE DAWLEY RAT; SURFACE PROPERTY; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; DRUG STABILITY; INTESTINAL ABSORPTION; INTESTINES; MALE; MEDICINE, CHINESE TRADITIONAL; MICELLES; MOLECULAR STRUCTURE; PERFUSION; PERMEABILITY; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES; XANTHONES;

EID: 84900850260     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.786723     Document Type: Article

References (39)

1. Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 2009;135:1777-82.
2. Zhang Z, Wang X, Ayman WY, et al. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery. Drug Deliv 2013; 20:86-93.
3. Wang XP, Lv HX, Waddad AY, et al. Studies on intestinal absorption kinetics of gambogic acid by rat single pass perfusion in situ. China J Chin Materia Medica 2012;37:2079-83.
4. Yi T, Yi Z, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008;68:1843-50.
5. Guo QL, Zhao L, Wu ZQ, et al. Eefect of gambogic acid on the hemopoietic and immune functions in experimental animals. Chin J Nat Med 2003;4:229-32.
6. Qu G, Zhu X, Zhang C, Ping Q. Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery. Drug Deliv 2009;16:363-70.
7. Saxena V, Hussain MD. Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Inter J Nanomed 2012;7:713-21.
8. 4 nanoparticles. Inter J Nanomed 2011;6:1929-35.
9. Cao J, Sun J, Wang X. N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm 2009; 35:1339-47.
10. Woitiski CB, Neufeld RJ, Soares AF, et al. Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. Drug Dev Ind Pharm 2012;38:1441-50.
11. Zhu X, Zhang C, Wu X, et al. Preparation, physical properties, and stability of gambogic acid-loaded micelles based on chitosan derivatives. Drug Dev Ind Pharm 2008;34:2-9.
12. Nishiyama N, Bae Y, Miyata K, et al. Smart polymeric micelles for gene and drug delivery. Drug Discov Today Technol 2005;2:21-6.
13. Nishiyama N, Kataoka K. Nanostructured devices based on block copolymer assemblies for drug delivery: designing structures for enhanced drug function. Adv Polym Sci 2006;193:67-101.
14. Merzlikine A, Rotter C, Rago B, et al. Effect of chitosan glutamate, arbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats. Drug Dev Ind Pharm 2009;35:1082-91.
15. Dai JG. The preparation of a kind of gambogic acid injection. CHN Patent CN 03131511.9. 2003.
16. Jin B, Dong H, Qiao L. The preparation of a kind of gambogic acid injection. CHN Patent CN 02124510.X. 2003.
17. You QD, Guo QL, Ke X, et al. The preparations of gambogic acid and its compound. CHN Patent CN03132386.3. 2003.
18. Zhao Y, Zhu J, Zhu S, et al. Synthesis and characterization of arginine-modified and europium-doped hydroxyapatite nanoparticle and its cell viability. Trans Nonferrous Met Soc China 2011;21: 1773-8.
19. Noh SM, Park MO, Shim G, et al. Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release 2010;145:159-64.
20. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005;57:559-77.
21. Liu C, Pan R, Jiang T, et al. Synthesis and characterization of N-octyl-N-arginine chitosan-a chitosan derivant with a mimetic structure of cell-penetrating peptides. Acta Pharmaceutica Sinica 2012;47:797-802.
22. Huo MR, Zhang Y, Zhou JP, et al. Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug. Inter J Pharm 2010;394:162-73.
23. Lv H, Zhang Z, Wang XP, et al. A biomimetic chitosan derivates: preparation, characterization and transdermal enhancement studies of N-arginine chitosan. Molecules 2011;16:6778-90.
24. Zhang Z, Abbad S, Pan R, et al. N-octyl-N-arginine chitosan micelles as an oral delivery system of insulin. J Biomed Nanotechnol 2012;9:1-9.
25. Xiao B, Wan Y, Zhao MQ, et al. Preparation and characterization of antimicrobial chitosan-N-arginine with different degrees of substitution. Carbohydr Polym 2011;83:144-50.
26. Hao K, Liu XQ, Wang GJ. Pharmacokinetics of gambogic acid in rats. J China Pharm Univ 2005;36:338-45.
27. Hassan EE, Parish RC, Gallo JM. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm Res 1992;9:390-7.
28. Li H, Huo M, Zhou J, et al. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci 2010;99:4543-53.
29. Hou W, Chen B, Zhao Y, Xiao W. Stability of gambogic acid. Chinese Traditional and Herbal Drugs 2011;42:1755-8.
30. Zhai X, Huang L, Song L, et al. Study on the rat intestinal absorption of rapamycin formulated in self-microemulsifying drug delivery system by single-pass intestinal perfusion technique. Chin Hosp Pharm J 2011;31:217-21.
31. Kenichi S, Kouki O, Mayumi Y, et al. High drug loading selfmicroemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation. Drug Dev Ind Pharm 2012;38:1254-61.
32. Dave RH, Patel AD, Donahue E, Patel HH. To evaluate the effect of addition of an anionic surfactant on solid dispersion using model drug indomethacin. Drug Dev Ind Pharm 2012;38:930-9.
33. Crouthame W, Sarapu A. Animal models for oral drug delivery in man. Washington, DC: American Pharmaceutical Association; 1983:27-106.
34. Sutton SC, Rinaldi MT, McCarthy JM, Vukovinsky KE. A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J Pharm Sci 2002;91:1046-53.
35. Berggren S, Hoogstraate J, Fagerholm U, Lennernas H. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur J Pharm Sci 2004;21:553-60.
36. Zakeri-Milani P, Valizadeha H, Tajerzadehc H, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharmaceut Sci 2007;10:368-79.
37. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996;13:1336-42.
38. Gilbert SB. Principles of drug absorption. Pinehurst (NC): Marcel Dekker, Inc. Modern Pharmaceutics: PharmaceuTech, Inc.; 2002:40-62.
39. Gordon LA, Hans L, Vinod PS, John RC. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12: 413-20.